Nyxoah Announces Acccess U.S. Pivotal Study Meets Primary Safety And Efficacy Endpoints In Complete Concentric Collapse Patients
NYXH•Pivotal study results
Sept. 2 (Reuters) - Nyxoah SA NYXH.BR:
- Nyxoah announces Acccess U.S. pivotal study meets primary safety and efficacy endpoints in complete concentric collapse patients
- Nyxoah reports 12-month ODI responder rate of 87.7% (P<0.001) on full analysis set
- Nyxoah reports 12-month AHI responder rate of 77.2% (P<0.001) on full analysis set
Source text: ID:nGNX5Qmj4X
Further company coverage: NYXH.BR
